Skip to content
10-K

Annual Report

Adamas Pharmaceuticals, Inc.

0001328143-21-000019

← back to feed
Filed
Feb 23, 2021 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding FY 2020 · Feb 16, 2021 30.57M sh
Capex FY 2020 · Dec 31, 2020 $0
Capex FY 2020 · Dec 31, 2019 $18K
Operating Cash Flow FY 2020 · Dec 31, 2020 −$50.71M
Operating Cash Flow FY 2020 · Dec 31, 2019 −$80.78M
Long Term Debt FY 2020 · Dec 31, 2020 $126.31M
Long Term Debt FY 2020 · Dec 31, 2019 $125.67M
Short Term Debt FY 2020 · Dec 31, 2020 $3.66M
Short Term Debt FY 2020 · Dec 31, 2019 $2.04M
Short Term Investments FY 2020 · Dec 31, 2020 $11.71M
Short Term Investments FY 2020 · Dec 31, 2019 $66.83M
Cash And Equivalents FY 2020 · Dec 31, 2020 $71.66M
Cash And Equivalents FY 2020 · Dec 31, 2019 $65.77M
Stockholders Equity FY 2020 · Dec 31, 2020 −$49.98M
Stockholders Equity FY 2020 · Dec 31, 2019 −$893K
Stockholders Equity FY 2020 · Dec 31, 2018 $89.89M
Current Liabilities FY 2020 · Dec 31, 2020 $34.87M
Current Liabilities FY 2020 · Dec 31, 2019 $26.95M
Total Liabilities FY 2020 · Dec 31, 2020 $170.01M
Total Liabilities FY 2020 · Dec 31, 2019 $163.05M
Current Assets FY 2020 · Dec 31, 2020 $111.74M
Current Assets FY 2020 · Dec 31, 2019 $150.32M
Total Assets FY 2020 · Dec 31, 2020 $120.03M
Total Assets FY 2020 · Dec 31, 2019 $162.16M
Sga Expense FY 2020 · Dec 31, 2020 $106.84M
Sga Expense FY 2020 · Dec 31, 2019 $114.37M
Rd Expense FY 2020 · Dec 31, 2020 $9.75M
Rd Expense FY 2020 · Dec 31, 2019 $30.03M
Net Income FY 2020 · Dec 31, 2020 −$57.4M
Net Income FY 2020 · Dec 31, 2019 −$105.19M
Operating Income FY 2020 · Dec 31, 2020 −$44.16M
Operating Income FY 2020 · Dec 31, 2019 −$92.24M
Cost Of Revenue FY 2020 · Dec 31, 2020 $2.04M
Cost Of Revenue FY 2020 · Dec 31, 2019 $2.47M
Revenue FY 2020 · Dec 31, 2020 $74.46M
Revenue FY 2020 · Dec 31, 2019 $54.64M